✅ Model Answer:
• Diagnosis: Febrile neutropenia — fever ≥38.3°C (or ≥38°C for 1 hour) in a child with ALL on chemotherapy, with ANC <500/µL (100/µL). Central line increases risk of bloodstream infection. Elevated CRP indicates bacterial infection risk.
• Any other test: Blood cultures from central line and peripheral vein (both sites), urine culture, stool culture (if diarrhea), serum electrolytes, lactate, procalcitonin, coagulation profile, chest X-ray (already done).
• What to do next: Admit to hospital. Start empiric IV antibiotics: antipseudomonal (cefepime 50 mg/kg/dose IV q8h OR piperacillin-tazobactam 100 mg/kg/dose IV q6h). Add vancomycin (15 mg/kg/dose IV q6h) if MRSA risk or central line infection suspected. Monitor for sepsis.
• Follow-up plan: Daily CBC, CRP, blood cultures. De-escalate antibiotics based on cultures and clinical status. G-CSF (granulocyte colony-stimulating factor) if prolonged neutropenia. Infectious disease consult. Continue antibiotics until ANC >500/µL and afebrile for 48 hours.

✅ Model Answer:
• Febrile neutropenia is defined as:
- Fever: Single temperature ≥38.3°C or ≥38°C for ≥1 hour
- Neutropenia: ANC <500/µL (or <1000/µL with expected decline)
• Risk factors:
- Malignancy: ALL, AML, lymphoma (chemotherapy-induced neutropenia)
- Chemotherapy: Intensity of regimen, myelosuppressive drugs
- Central venous catheter: Central line increases infection risk
- Age: Younger children may have more severe neutropenia
- Underlying disease: Relapsed/refractory disease, bone marrow involvement
- Previous infections: History of febrile neutropenia episodes
- Mucositis: Increased risk of bacterial translocation
- Environmental factors: Recent hospitalization, antibiotic exposure

✅ Model Answer:
• Gram-positive organisms:
- Coagulase-negative staphylococci (most common, especially central line-associated)
- Staphylococcus aureus (MRSA risk)
- Streptococcus viridans (mucositis-associated)
- Enterococcus (vancomycin-resistant enterococci — VRE)
- Streptococcus pneumoniae
• Gram-negative organisms:
- Escherichia coli (most common gram-negative)
- Pseudomonas aeruginosa (severe, requires antipseudomonal coverage)
- Klebsiella pneumoniae (ESBL producers)
- Enterobacter species
- Serratia marcescens
- Acinetobacter baumannii
• Fungal organisms:
- Candida species (especially with prolonged neutropenia)
- Aspergillus species (pulmonary, sinus)

✅ Model Answer:
• Empiric antibiotic regimen:
- Antipseudomonal agent:
• Cefepime: 50 mg/kg/dose IV q8h (first-line)
• Piperacillin-tazobactam: 100 mg/kg/dose IV q6h (alternative)
• Meropenem: 20-40 mg/kg/dose IV q8h (if ESBL risk or severe)
- Vancomycin: 15 mg/kg/dose IV q6h (add if MRSA risk, central line infection, hemodynamic instability, or positive gram-positive cultures)
- Antifungal: If prolonged fever >4-5 days, consider empiric antifungal (caspofungin, liposomal amphotericin B, or voriconazole).
• Duration: Continue until ANC >500/µL and afebrile for ≥48 hours.
• De-escalation: If cultures are negative and patient improves, consider stopping vancomycin and narrowing antibiotics based on susceptibilities.

✅ Model Answer:
• G-CSF (filgrastim):
- Mechanism: Stimulates neutrophil production in the bone marrow.
- Indications:
• Prophylactic use in patients at high risk for febrile neutropenia (based on chemotherapy regimen).
• Not routinely recommended for treatment of established febrile neutropenia (unless severe infection or prolonged neutropenia).
- Dosing: 5 µg/kg/day SC or IV until ANC >500/µL.
- Benefits: Reduces duration of neutropenia and hospital stay.
- Risks: Bone pain, splenomegaly, potential risk of secondary malignancies (with prolonged use).
- Contraindications: Not recommended in patients receiving concurrent chemotherapy with radiotherapy.

✅ Model Answer:
• Complications:
- Sepsis and septic shock: Most serious complication — can be rapidly fatal
- Central line-associated bloodstream infection (CLABSI): Requires line removal if persistent bacteremia
- Pneumonia: Bacterial or fungal (especially with prolonged neutropenia)
- Typhlitis (neutropenic enterocolitis): Inflammation of the cecum, abdominal pain, diarrhea (can be life-threatening)
- Mucositis: Painful oral ulceration, increased risk of bacterial translocation
- Fungal infections: Invasive candidiasis, aspergillosis (prolonged neutropenia >10 days)
- Hemorrhagic complications: Thrombocytopenia (due to chemotherapy)
- Prolonged hospitalization: Increased risk of secondary infections
- Death: Mortality 5-10% in febrile neutropenia (higher with septic shock)

✅ Model Answer:
• Indications for central line removal:
- Persistent bacteremia: >48-72 hours on appropriate antibiotics
- Candida bloodstream infection (candidemia): Always remove the line
- Occlusion: Inability to aspirate blood or infuse through the line
- Mechanical complications: Thrombosis, extravasation, fracture
- Catheter-site infection: Tunnel infection, port pocket abscess, or exit site infection with purulence
- Severe sepsis or septic shock: When the line is suspected as the source
- Persistent fever: No source identified after 3-5 days with positive cultures
• Timing: Decision should be made in consultation with oncology and infectious disease teams.

✅ Model Answer:
• Prognosis:
- Good: With prompt antibiotic therapy and supportive care (mortality <5-10%)
- Severe: Prolonged neutropenia, septic shock, and multidrug-resistant infections worsen prognosis
- Underlying malignancy: Relapse risk, overall survival depends on cancer control
- Mortality: Higher in patients with gram-negative sepsis (especially Pseudomonas) and fungal infections
• Long-term follow-up:
- Oncology: Continue chemotherapy as planned (may need dose modifications based on neutropenia)
- Infectious disease: Monitor for recurrent infections
- Vaccination: Review immunization status (especially after chemotherapy)
- Growth and development: Monitor for effects of chemotherapy
- Psychological support: For the child and family
- Prophylaxis: Consider prophylactic antibiotics (fluconazole, TMP-SMX) during chemotherapy cycles